Michael Gerard McCusker Jr., MD

Unless otherwise indicated, this information has been self-reported and has not been verified by the Board of Medicine.

None Reported

None Reported

How I treat ALK positive non-small cell lung cancer
ESMO Open
Volume: 4
Date: 07 2019

Proton beam therapy and immune checkpoint inhibitors in malignant pleural mesothelioma: Are we ready for the combination?
J Thorac Oncol
Volume: 14
Date: 09 2019

Concomitant medications during immune checkpoint blockage in cancer patients: Novel insights in this emerging clinical scenario
Crit Rev Oncol Hematol
Volume: 142
Date: 10 2019

RET fusions in solid tumors
Cancer Treat Rev
Volume: 81
Date: 12 2019

Immunotherapy in lung cancer: From a minor god to the Olympus
Adv Exp Med Biol
Volume: 1244
Date: 01 2020

Potential of pembrolizumab in metastatic of recurrent head and neck cancer: Evidence to date
Onc Targets Ther
Volume: 13
Date: 04 2020

New targets in lung cancer (excluding EGFR, ALK, ROS1)
Curr Oncol Rep
Volume: 22
Date: 05 2020

Eosinophilic myocarditis in a patient with multiple myeloma
Clin Lymphoma Myeloma Leuk
Date: 07 2020

Development of autoimmune diabetes with severe diabetic ketoacidosis and immune-related thyroiditis secondary to durvalumab: A case report
Transl Lung Cancer Res
Volume: 9
Date: 10 2020

Emerging immune checkpoint inhibitors for the treatment of head and neck cancers
Expert Opin Emerg Drugs
Volume: 25
Date: 12 2020